576 related articles for article (PubMed ID: 29170503)
1. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
Lauss M; Donia M; Harbst K; Andersen R; Mitra S; Rosengren F; Salim M; Vallon-Christersson J; Törngren T; Kvist A; Ringnér M; Svane IM; Jönsson G
Nat Commun; 2017 Nov; 8(1):1738. PubMed ID: 29170503
[TBL] [Abstract][Full Text] [Related]
2. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
Roszik J; Haydu LE; Hess KR; Oba J; Joon AY; Siroy AE; Karpinets TV; Stingo FC; Baladandayuthapani V; Tetzlaff MT; Wargo JA; Chen K; Forget MA; Haymaker CL; Chen JQ; Meric-Bernstam F; Eterovic AK; Shaw KR; Mills GB; Gershenwald JE; Radvanyi LG; Hwu P; Futreal PA; Gibbons DL; Lazar AJ; Bernatchez C; Davies MA; Woodman SE
BMC Med; 2016 Oct; 14(1):168. PubMed ID: 27776519
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
4. Adoptive cell transfer as personalized immunotherapy for human cancer.
Rosenberg SA; Restifo NP
Science; 2015 Apr; 348(6230):62-8. PubMed ID: 25838374
[TBL] [Abstract][Full Text] [Related]
5. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
[TBL] [Abstract][Full Text] [Related]
7. Is antigen specificity the key to efficient adoptive T-cell therapy?
Labarriere N; Khammari A; Lang F; Dreno B
Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
[TBL] [Abstract][Full Text] [Related]
8. [Future of malignant stage I melanoma. Immunology and immunotherapy].
Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
[No Abstract] [Full Text] [Related]
9. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
Front Immunol; 2020; 11():1147. PubMed ID: 32582212
[TBL] [Abstract][Full Text] [Related]
10. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.
Phan GQ; Rosenberg SA
Cancer Control; 2013 Oct; 20(4):289-97. PubMed ID: 24077405
[TBL] [Abstract][Full Text] [Related]
12. Probing T-cell Infiltration in Tumors.
Cancer Discov; 2017 Jan; 7(1):5-6. PubMed ID: 27927681
[TBL] [Abstract][Full Text] [Related]
13. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
Radvanyi LG; Bernatchez C; Zhang M; Fox PS; Miller P; Chacon J; Wu R; Lizee G; Mahoney S; Alvarado G; Glass M; Johnson VE; McMannis JD; Shpall E; Prieto V; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Patel S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Davies MA; Mansaray R; Fulbright OJ; Toth C; Ramachandran R; Wardell S; Gonzalez A; Hwu P
Clin Cancer Res; 2012 Dec; 18(24):6758-70. PubMed ID: 23032743
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen landscape dynamics during human melanoma-T cell interactions.
Verdegaal EM; de Miranda NF; Visser M; Harryvan T; van Buuren MM; Andersen RS; Hadrup SR; van der Minne CE; Schotte R; Spits H; Haanen JB; Kapiteijn EH; Schumacher TN; van der Burg SH
Nature; 2016 Aug; 536(7614):91-5. PubMed ID: 27350335
[TBL] [Abstract][Full Text] [Related]
15. Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.
Prickett TD; Crystal JS; Cohen CJ; Pasetto A; Parkhurst MR; Gartner JJ; Yao X; Wang R; Gros A; Li YF; El-Gamil M; Trebska-McGowan K; Rosenberg SA; Robbins PF
Cancer Immunol Res; 2016 Aug; 4(8):669-78. PubMed ID: 27312342
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.
Foley KC; Nishimura MI; Moore TV
Melanoma Res; 2018 Jun; 28(3):171-184. PubMed ID: 29521881
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.
Ma C; Cheung AF; Chodon T; Koya RC; Wu Z; Ng C; Avramis E; Cochran AJ; Witte ON; Baltimore D; Chmielowski B; Economou JS; Comin-Anduix B; Ribas A; Heath JR
Cancer Discov; 2013 Apr; 3(4):418-29. PubMed ID: 23519018
[TBL] [Abstract][Full Text] [Related]
20. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
